3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Breast
3
Thoracic
2
Sarcoma
2
Gynecologic
2
Genitourinary
2
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
30
Docetaxel
10
Cetuximab
10
Trastuzumab
9
Paclitaxel
7
Nivolumab
6
Magnetic Resonance Spectroscopy
6
palbociclib
5
cemiplimab
5
Gemcitabine
5
Cyclophosphamide
5
Carboplatin
5
Capecitabine
5
Biopsy
5
durvalumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiotherapy
4
Fulvestrant
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cisplatin
4
selpercatinib
3
poly ICLC
3
pazopanib
3
fludarabine
3
avelumab
3
Taxes
3
Sunitinib
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
alectinib
×
Head & Neck
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts